✨
AI Summary
- FDA faces drama over HHS plan to allow temporary compounding of unapproved peptides.
- FDA intends to acknowledge individual NDA and BLA filings, increasing transparency.
- Discussions on potential legal challenges to the new FDA transparency policy.
Guests on This Episode
BS
Bridget Silverman
4 podcast appearances
DG
Derrick Gingery
8 podcast appearances
MO
Maaisha Osman
4 podcast appearances
SS
Sue Sutter
8 podcast appearances
More from Citeline Podcasts
